879 related articles for article (PubMed ID: 24439788)
1. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
2. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
3. Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.
Vickers AJ; Sjoberg DD; Ulmert D; Vertosick E; Roobol MJ; Thompson I; Heijnsdijk EA; De Koning H; Atoria-Swartz C; Scardino PT; Lilja H
BMC Med; 2014 Feb; 12():26. PubMed ID: 24512643
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
5. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study.
Zappa M; Ciatto S; Bonardi R; Mazzotta A
Ann Oncol; 1998 Dec; 9(12):1297-300. PubMed ID: 9932159
[TBL] [Abstract][Full Text] [Related]
6. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
7. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Screening.
Catalona WJ
Med Clin North Am; 2018 Mar; 102(2):199-214. PubMed ID: 29406053
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
[TBL] [Abstract][Full Text] [Related]
11. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
12. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.
Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
Eur Urol Oncol; 2021 Oct; 4(5):731-739. PubMed ID: 34364829
[TBL] [Abstract][Full Text] [Related]
13. 2022 Update on Prostate Cancer Epidemiology and Risk Factors-A Systematic Review.
Bergengren O; Pekala KR; Matsoukas K; Fainberg J; Mungovan SF; Bratt O; Bray F; Brawley O; Luckenbaugh AN; Mucci L; Morgan TM; Carlsson SV
Eur Urol; 2023 Aug; 84(2):191-206. PubMed ID: 37202314
[TBL] [Abstract][Full Text] [Related]
14. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
[TBL] [Abstract][Full Text] [Related]
15. Trade-Off between Treatment of Early Prostate Cancer and Incidence of Advanced Prostate Cancer in the Prostate Screening Era.
Shen X; Kumar P
J Urol; 2016 May; 195(5):1397-1402. PubMed ID: 26656266
[TBL] [Abstract][Full Text] [Related]
16. Cancer overdiagnosis and overtreatment.
Klotz L
Curr Opin Urol; 2012 May; 22(3):203-9. PubMed ID: 22472510
[TBL] [Abstract][Full Text] [Related]
17. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
Pienta KJ
Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
[TBL] [Abstract][Full Text] [Related]
18. Overdiagnosis and Lives Saved by Reflex Testing Men With Intermediate Prostate-Specific Antigen Levels.
Gulati R; Morgan TM; A'mar T; Psutka SP; Tosoian JJ; Etzioni R
J Natl Cancer Inst; 2020 Apr; 112(4):384-390. PubMed ID: 31225597
[TBL] [Abstract][Full Text] [Related]
19. Should prostate-specific antigen screening be offered to asymptomatic men?
van Vugt HA; Bangma CH; Roobol MJ
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]